Cargando…

Allogeneic hematopoietic stem cell transplantation with the modified myeloablative conditioning regimen for children with chronic active Epstein–Barr virus infection

IMPORTANCE: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is considered the only effective treatment for chronic active Epstein–Barr virus infection (CAEBV). The clinical efficacy and safety of allo‐HSCT with different conditioning regimens in children with CAEBV remain unclear. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Yanhui, Wei, Ang, Wang, Bin, Zhu, Guanghua, Zhang, Rui, Jia, Chenguang, Yan, Yan, Zhou, Xuan, Yang, Jun, Qin, Maoquan, Wang, Tianyou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789936/ https://www.ncbi.nlm.nih.gov/pubmed/36582272 http://dx.doi.org/10.1002/ped4.12350

Ejemplares similares

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
por: Atilla, Erden, et al.
Publicado: (2017)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Cognitive and psychological outcomes of pediatric allogeneic hematopoietic stem cell transplantation survivors in a single center in China
por: Luo, Yanhui, et al.
Publicado: (2019)

Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein–Barr virus infection
por: Ma, Honghao, et al.
Publicado: (2021)

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation
por: Wu, Xiu-li, et al.
Publicado: (2012)

Variable clinical manifestations of hematopoietic stem cell transplant‐associated thrombotic microangiopathy
por: Jia, Chenguang, et al.
Publicado: (2019)

Immune Reconstitution in Pediatric Aplastic Anemia after Allogeneic Hematopoietic Stem-cell Transplantation
por: Wang, Jiayu, et al.
Publicado: (2022)

Primary Graft Failure after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
por: Olsson, Richard F., et al.
Publicado: (2015)

Successful treatment of immediate allogeneic myeloablative hematopoietic stem cell transplantation from a HLA-mismatched sibling donor for active systemic epstein–barr virus-positive T-cell lymphoproliferative disease of childhood following primary acute epstein–barr virus infection
por: Kakinoki, Yasutaka, et al.
Publicado: (2015)

Association of Epstein-Barr virus infection with allogeneic hematopoietic stem cell transplantation in patients in Portugal
por: Marinho-Dias, Joana, et al.
Publicado: (2019)

Haploidentical haematopoietic stem cell transplantation for malignant infantile osteopetrosis and intermediate osteopetrosis: a retrospective analysis of a single centre
por: Zhu, Guanghua, et al.
Publicado: (2021)

Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
por: Çiftçiler, Rafiye, et al.
Publicado: (2019)

Haploidentical hematopoietic stem cell transplantation using reduced‐intensity conditioning for pediatric patients with familial hemophagocytic lymphohistiocytosis
por: Jia, Chenguang, et al.
Publicado: (2019)

Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies
por: Xuan, Li, et al.
Publicado: (2012)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

SIMILAR OUTCOMES USING MYELOABLATIVE VERSUS REDUCED INTENSITY ALLOGENEIC TRANSPLANT PREPARATIVE REGIMENS FOR AML OR MDS
por: Luger, Selina M., et al.
Publicado: (2011)

Management of Epstein–Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation
por: Liu, Li, et al.
Publicado: (2020)

Allogeneic hematopoietic stem cell transplantation in congenital hemoglobinopathies with myeloablative conditioning and rabbit anti-thymocyte globulin
por: Park, Bo-Kyoung, et al.
Publicado: (2018)

Features of Epstein–Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen
por: Ru, Yuhua, et al.
Publicado: (2022)

1601. Effect of Preemptive Rituximab Therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem Cell Pediatric Transplants
por: Catho, Gaud, et al.
Publicado: (2018)

Across the Myeloablative Spectrum: Hematopoietic Cell Transplant Conditioning Regimens for Pediatric Patients with Sickle Cell Disease
por: Limerick, Emily, et al.
Publicado: (2022)

Applying Rituximab During the Conditioning Regimen Prevents Epstein–Barr Virus Infection Following Allogeneic Hematopoietic Stem Cell Transplant in a Children’s Cohort: A Retrospective Case–Control Study
por: Ruan, Yongsheng, et al.
Publicado: (2023)

Low-Dose Decitabine Monotherapy Reverses Mixed Chimerism in Adult Patients After Allogeneic Hematopoietic Stem Cell Transplantation With Myeloablative Conditioning Regimen: A Pilot Phase II Study
por: Wang, Ling, et al.
Publicado: (2021)

Cyclosporine A trough concentrations are associated with acute GvHD after non-myeloablative allogeneic hematopoietic cell transplantation
por: de Kort, Elizabeth A., et al.
Publicado: (2019)

Infusion of Host-Derived Unlicensed NK Cells Improves Donor Engraftment in Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation
por: Alvarez, Maite, et al.
Publicado: (2021)

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades
por: Cooper, Jason P., et al.
Publicado: (2020)

Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein–Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant
por: Diop, Ndeye Soukeyna, et al.
Publicado: (2021)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation
por: Nakamura, R, et al.
Publicado: (2002)

Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation
por: Zhou, Jing-Rui, et al.
Publicado: (2021)

Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis
por: Kołodziejczak, Michalina, et al.
Publicado: (2021)

Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab
por: Wei, Na, et al.
Publicado: (2021)

Lineage-specific chimerism analysis in nucleated cells, T cells and natural killer cells after myeloablative allogeneic hematopoietic stem cell transplantation
por: Goh, Ri-Young, et al.
Publicado: (2011)

A gut microbiota score predicting acute graft‐versus‐host disease following myeloablative allogeneic hematopoietic stem cell transplantation
por: Han, Lijie, et al.
Publicado: (2019)

Clinical value of plasma and peripheral blood mononuclear cells Epstein–Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation
por: Zhou, Xi, et al.
Publicado: (2022)

Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma
por: Campbell, P, et al.
Publicado: (2014)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide
por: Fu, Hua-Rui, et al.
Publicado: (2021)

Pilot experience with opebacan/rBPI (21) in myeloablative hematopoietic cell transplantation
por: Guinan, Eva, et al.
Publicado: (2015)

The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation
por: Uppugunduri, Chakradhara Rao S., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_u0ise5kl5po7lfn5kqgaf6b7uc